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BACKGROUND: Calculating the maximum heart rate for age is one method to characterize the maximum effort of an individual. Al-
though this method is commonly used, little is known about heart rate dynamics in optimized beta-blocked heart failure patients. 
AIM: The aim of this study was to evaluate heart rate dynamics (basal, peak and % heart rate increase) in optimized beta-blocked 
heart failure patients compared to sedentary, normal individuals (controls) during a treadmill cardiopulmonary exercise test. 
METHODS: Twenty-five heart failure patients (49±11 years, 76% male), with an average LVEF of 30±7%, and fourteen controls 
were included in the study. Patients with atrial fibrillation, a pacemaker or noncardiovascular functional limitations or whose drug 
therapy was not optimized were excluded. Optimization was considered to be 50 mg/day or more of carvedilol, with a basal heart 
rate between 50 to 60 bpm that was maintained for 3 months. 
RESULTS: Basal heart rate was lower in heart failure patients (57±3 bpm) compared to controls (89±14 bpm; p<0.0001). Simi-
larly, the peak heart rate (% maximum predicted for age) was lower in HF patients (65.4±11.1%) compared to controls (98.6±2.2; 
p<0.0001). Maximum respiratory exchange ratio did not differ between the groups (1.2±0.5 for controls and 1.15±1 for heart failure 
patients; p=0.42). All controls reached the maximum heart rate for their age, while no patients in the heart failure group reached the 
maximum. Moreover, the % increase of heart rate from rest to peak exercise between heart failure (48±9%) and control (53±8%) 
was not different (p=0.157). 
CONCLUSION: No patient in the heart failure group reached the maximum heart rate for their age during a treadmill cardiopul-
monary exercise test, despite the fact that the percentage increase of heart rate was similar to sedentary normal subjects. A heart 
rate increase in optimized beta-blocked heart failure patients during cardiopulmonary exercise test over 65% of the maximum 
age-adjusted value should be considered an effort near the maximum. This information may be useful in rehabilitation programs 
and ischemic tests, although further studies are required.
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BACKGROUND
Heart failure (HF) is considered the last stage of heart 
disease and a significant cause of worldwide mortality 
and morbidity.1 In recent years, beta-blocking therapy has 
become a primary pharmacologic intervention in patients 
with HF. The prescription of beta-blockers arises from an 
abundance of evidence demonstrating that beta-blocking 
therapy improves survival and reduces hospitalization2, 
although improvement in aerobic capacity has not been 
proved.3
Cardiopulmonary exercise testing is a well-established 
technique to evaluate peak oxygen consumption (pVO2) in 
HF patients. This variable is the best prognostic factor in 
HF patients, even in the beta-blocking era.4 Aerobic exercise 
training is also a well-established nonpharmacological 
method to increase pVO2 in HF patients. In the HF 
population, prescription of adequate aerobic effort relative 
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to intensity based on heart rate (HR) is crucial to obtain both 
an increase in exercise capacity and a reasonable control of 
exercise-related risks.1
The maximum HR adjusted for age (220 – age) is 
commonly used to characterize a maximum effort in 
normal subjects.5 Although the HR dynamics are known 
in non-optimized carvedilol HF patients6, little is known 
in optimized beta-blocked HF patients. The aim of this 
study is to evaluate HR dynamics (basal, peak and the 
percentage increase of HR) in optimized beta-blocked HF 
patients compared to normal individuals during a treadmill 
cardiopulmonary exercise test.
MATERIALS AND METHODS
Study population
A total of 25 (76% male, 24% female) HF patients 
(49±11 years) having an average left ventricle ejection 
fraction of 30±7% (determined by echocardiography), and 
14 (36% male, 64% female) sedentary normal individuals 
(control group) (30±6 years) were included in the study. Data 
were collected from March 2006 to September 2007. HF 
patient characteristics are listed in Tables 1 and 2. Patients 
with atrial fibrillation, a pacemaker, or noncardiovascular 
functional limitations such as osteoarthritis, chronic 
obstructive pulmonary disease and patients whose drug 
therapy was not optimized were excluded from this study. 
Optimization was considered to be 50 mg/day or more of 
carvedilol and a resting HR between 50 and 60 beats per 
minute, maintained for at least 3 months.7
This protocol was approved by the Ethical Committee 
of Instituto do Coração do Hospital das Clínicas da 
Faculdade de Medicina da Universidade de São Paulo (InCor 
HCFMUSP). All patients provided informed consent prior 
to participation.
Cardiopulmonary exercise test
Patients and normal subjects were asked to refrain from 
both strenuous physical activities and the consumption of 
any stimulants (coffee, tobacco, alcohol) that could influence 
heart rate for 24 hours prior to the cardiopulmonary exercise 
test. The patients’ last meals were ingested at least 2 hours 
before the start of the test. All subjects underwent the 
cardiopulmonary exercise test on a programmable treadmill 
(Series 2000; Marquette Electronics; Milwaukee, WI, USA) 
in a temperature-controlled room (21-23ºC) between 10:00 
a.m. and 15:00 p.m. with a standard 12 lead continuous 
electrocardiogram monitor (Max 1; Marquette Electronics). 
Blood pressure monitoring was performed by the auscultation 
method. Minute ventilation (VE), oxygen uptake (VO2), 
carbon dioxide output (VCO2) and other cardiopulmonary 
variables were acquired breath-by-breath by a computerized 
system (Vmax 229 model, SensorMedics, Yorba Linda, CA, 
USA). Resting VO2 and HR were computed as the mean of 
the final 30 seconds of the resting period, while peak effort 
pVO2 and heart rate (peakHR) were the mean values of the 
final 30 seconds of effort before exhaustion. The respiratory 
Table 1 - Subject characteristics
Heart Failure (25) Controls (14) p-value
Age 49±11 years 30±6 years <0.0001
Peak oxygen consumption 19±6 mLO2.kg-1.min-1 31±4 mL O2 kg-1 mim-1 <0.0001
Body mass index 23±2 kg/m2 22±1 kg/m2 p=0.18
Basal HR 57±3 bpm 89±14 bpm <0.0001
Peak HR (% maximum predicted for age) 65.4±11.1% 98.6±2.2% <0.0001
HR percentage increase 48±9% 53±8% p=0.157
Table 2 - Characteristics of heart failure patients
Characteristics of heart failure patients Number of patients 
(%), dose (mg/day)
Etiology:
 Ischemic 42%
 Idiopathic dilated cardiomyopathy 44%
 Hypertensive 14%
NYHA functional class:
 I 42%
 II 42%
 III 16%
Left ventricle ejection fraction 30±7%
Current medications:
Diuretics 
 Furosemide 64%, 52±30mg/day
 hydrochlorothiazide 48%, 43±24md/day
ACE inhibitors 
 Enalapril 64%, 38±6mg/day
 Captopril 20%, 93±37mg/day
Angiotensin II AT1 receptor antagonists 
(losartan) 
16%, 75±29mg/day
b-adrenergic receptor blocker (carvedilol) 100%, 50±0mg/day
Spironolactone 28%, 25±0mg/day
Digoxin 44%, 0.25±0mg/day
Isosorbide 5-mononitrate 20%, 56±35mg/day
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exchange ratios (RER) were recorded as the averaged 
samples obtained during each stage of the protocol in both 
HF patients and normal subjects (Naughton and Balke 4.0, 
respectively). A satisfactory cardiopulmonary exercise test 
was characterized by RER>1.05 and symptoms of maximum 
effort. Maximum HR predicted for age was calculated by the 
equation: 220 – age.
Current medication intake
All HF patients were receiving a beta-blocker (carvedilol) 
associated with ACE inhibitors (enalapril) or angiotensin II 
AT1 receptor antagonists (losartan). The medication profile 
of the HF patient group is shown in Table 2. Patients took 
beta-blockers, ACE inhibitors, Angiotensin II AT1 receptor 
antagonists and Isosorbide 5-mononitrate two times per day, 
one half of the daily dose in the morning (9:00 a.m.) and 
the other half at night (9:00 p.m.). Diuretics, digoxin and 
spironolactone were taken in the morning (9:00 a.m.).
STATISTICAL ANALYSIS
The descriptive analysis was presented as the mean, 
standard deviation and 95% Confidence Interval (CI). The 
basal HR, percentage HR increase during cardiopulmonary 
test and peak HR (% maximum predicted for age) for heart 
failure patients and controls were normally distributed. To 
compare these variables, we used the unpaired student’s 
t-test.
Data were analyzed using the Statistical Package for 
Social Sciences (SPSS) for Windows, v 11.5 (SPSS Inc, 
Chicago, Ill). Statistical significance was set at p < 0.05.
RESULTS 
All subjects performed a satisfactory cardiopulmonary 
exercise test (RER 1.2±0.5 in normals and 1.15±1 in HF 
patients; p=0.42). The basal HR was lower in optimized 
beta-blocked HF patients (57±3 bpm) compared to controls 
(89±14 bpm) (p<0.0001), as also seen with peak HR (% 
maximum predicted for age) (65.4±11.1% for HF and 
98.6±2.2 for controls; p<0.0001). All controls reached the 
maximum HR for their age, while no patients in the HF 
group did. Moreover, the percentage increase of HR from 
rest to peak exercise between HF (48±9%) and control 
groups (53±8%) was not different (p=0.157) (Figure 1).
DISCUSSION
The main finding of this study is the observation that 
all controls reached the maximum HR for their age, while 
Figure 1 - Data are presented by mean ± 95% of confidence interval. A: Basal 
HR between controls and heart failure group; B: Mean of HR percentage 
increase between controls and heart failure group and C: Mean of peak HR 
(%maximum predicted for age). * significant values (<0.05)
none of the patients in the HF group were able to do so. 
Moreover, no difference was seen between the percentage 
increase of HR from rest to peak exercise between HF and 
control groups. 
HR variability has been studied as a non-invasive tool 
to assess cardiac autonomic control of the nervous system, 
and it is proposed to reflect the interaction of sympathetic 
and parasympathetic (vagal) activity.8 Exercise training in 
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sedentary subjects affects this control, as carvedilol do in HF 
patients.9 The HR dynamics in optimized HF patients and 
the percentage of HR increase during the cardiopulmonary 
exercise test is unknown. Achievement of age-predicted 
values for maximal HR during exercise is often used as a 
reflection of maximal or near maximal effort (220 - age).5 
This method has been questioned by some authors,10 but it is 
currently the most commonly-used method in the world. 
In our study, all sedentary subjects in the normal group 
reached the maximum HR for the age in the cardiopulmonary 
exercise test, while no patients in the HF group were able to 
reach. HR increased by only 65% of the maximum age-
predicted HR in the HF group and 98% in the normal group. 
This is in partial agreement with Mezzani et al, who observed 
a HR increase of 76% of the maximum age-predicted in their 
non-optimized beta-blocker dose HF group and a 93% of 
the maximum age-predicted increase in the control group. 
The difference in HR increase in HF patients observed by 
Mezzani et al and our study is attributed to carvedilol dose 
optimization. The HR increase in the normal group of his 
study was similar to our results, as expected. Brawner et al 
designed a study to test the hypothesis that the percentage 
of HR reserve (peak HR – rest HR) was equivalent to the 
percentage of VO2 reserve during treadmill exercise among 
patients with a history of myocardial infarction, a group of 
patients with HF and a group with subjects with risk factors 
for heart diseases. In this study, the authors showed that the 
peak HR was higher in non-beta-blocked HF patients than 
in beta-blocked patients (143±3 bpm versus 125±4 bpm 
p<0.01), while the HR reserve was the same (52±3 versus 
50±3, p=NS). The authors did not calculate the percentage 
of HR increase or compare any of these variables with the 
cardiovascular risk factors group.11
Our data suggest that the maximum HR predicted for age 
(220 – age) should not be used to characterize a maximum 
effort in optimized beta-blocked HF patients. Despite this, 
the percentage increase of HR from rest to peak exercise 
between HF and control groups was not different. Thus, 
a peak HR of 65% of the maximum HR predicted for age 
should be considered to characterize and estimate a near-
maximal effort in HF patients undergoing optimized beta-
blocking therapy, rather than the currently used definition of 
90 to 100% of 220-age. This equation (65% (220 – age)) has 
never been evaluated previously. We hypothesized that the HR 
percentage increase was the same in HF patients and controls 
because the optimized beta-blocked HF patients started the 
cardiopulmonary exercise test with a basal HR (effect of 
carvedilol) lower than the normal group, despite the fact that 
the maximum HR calculated by age was not reached.
CONCLUSION
In the treadmill cardiopulmonary exercise test, optimized 
beta-blocked HF patients had both basal and peak HRs 
that were lower than control. No patient in the HF group 
reached the maximum HR predicted by the age, despite 
the fact that the percentage HR increase was the same as 
in sedentary normal subjects. In HF patients undergoing 
optimized beta-blocking therapy, the maximum HR during 
cardiopulmonary exercise test should be set as 65% of 
220 - age to characterize and estimate near-maximal effort 
during the exercise treadmill test. This information may 
also be useful in rehabilitation programs and ischemic tests, 
although further studies are required.
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